Allarity Therapeutics (ALLR) Convertible Debt (2020 - 2025)
Allarity Therapeutics' (ALLR) quarterly Convertible Debt came in at $1.4 million in Q4 2025, up 3.7% YoY from $1.3 million in Q4 2024, and up 3.7% on a QoQ basis from $1.3 million in Q4 2024.
Allarity Therapeutics (ALLR) Convertible Debt (2020 - 2025) Analysis & Trends
Allarity Therapeutics (ALLR) has 6 years of Convertible Debt data on file, last reported at $1.4 million in Q4 2025.
- Quarterly Convertible Debt rose 3.7% year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (up 3.7% YoY) and the FY2025 annual result came in at $1.4 million, up 3.7% from the prior year.
- Convertible Debt advanced to $1.4 million in Q4 2025, from $1.3 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $1.4 million in Q4 2025 to a low of $773000.0 in Q3 2021.
- A 5-year average of $1.1 million and a median of $1.1 million in 2022 frame the typical range for Convertible Debt.
- Annual changes were most pronounced in 2023 — Convertible Debt fell 17.12% — and 2024, when it jumped 54.94%.
- Tracing ALLR's Convertible Debt over 5 years: stood at $1.0 million in 2021, then increased by 8.3% to $1.1 million in 2022, then gained by 20.04% to $1.3 million in 2023, then advanced by 3.85% to $1.3 million in 2024, then advanced by 3.7% to $1.4 million in 2025.
- The last three Convertible Debt figures came in at $1.4 million (Q4 2025), $1.3 million (Q4 2024), and $1.3 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Allarity Therapeutics | 23.23 Mn | 23.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.40 Mn |
| Dec 31, 2024 | 1.35 Mn |
| Jun 30, 2024 | 1.33 Mn |
| Mar 31, 2024 | 1.32 Mn |
| Dec 31, 2023 | 1.30 Mn |
| Sep 30, 2023 | 876,000.00 |
| Jun 30, 2023 | 863,000.00 |
| Mar 31, 2023 | 850,000.00 |
| Dec 31, 2022 | 1.08 Mn |
| Sep 30, 2022 | 1.06 Mn |
| Dec 31, 2021 | 1.00 Mn |
| Sep 30, 2021 | 773,000.00 |
| Dec 31, 2020 | 737,000.00 |